Citations 2
Health system patterns of imaging and fluid biomarker testing in the era of anti‐amyloid therapies
Robb, W Hudson , Kaur, Gurkiran , Huang, Steven K. , Martínez, Felipe Derteano, Nguyen, Ba Thang, Shin, Clifford , Conyers, Christopher T. , Grilli, Christopher, Upjohn, David P., Ortega, V E, Hohman, Timothy J., Keegan, Richard, Cogswell, Petrice M., Graff‐Radford, Jonathan, Johnson, Derek R., Ramanan, Vijay K., Koran, Mary Ellen, Huang, Steven, Nguyen, Ba, Shin, Clifford H, Grilli, Christopher B, Koran, Mary Ellen , Martinez, Felipe, Nguyen, Ba, Yang, Ming , Hohman, Timothy J. , Parent, Ephraim E. , Cogswell, Petrice M. , Graff‐Radford, Jonathan , Ramanan, Vijay K. , Koran, Mary Ellen I.
Alzheimer's & Dementia | April 8, 2026 | Volume: 22 | Issue: 4 | Pages: No page available
Abstract INTRODUCTION Anti—amyloid‐β (Aβ) therapies are reshaping Alzheimer's disease (AD) management. Understanding changes in real‐world patterns of diagnostic testing and infusion chair usage is essential for optimizing access to care. METHODS Retrospective analysis of Mayo Clinic enterprise electronic health records (Jan 2019–Mar 2025) assessed trends in AD‐relevant brain imaging, fluid biomarkers, apolipoprotein E (APOE) testing, and lecanemab infusions. Rates of amyloid‐beta (Aβ) positivity by sex and age, APOE genotype frequencies, and lecanemab treatment initiation and discontinuation were evaluated. RESULTS Following national insurance coverage changes, lecanemab infusions grew by 110 infusions per quarter to 605 in Q1 2025. Aβ positron emission tomography scans increased (+22/quarter), cerebrospinal fluid biomarker orders declined (−25/quarter), and plasma p‐tau 217 orders rapidly increased (+238/quarter). Females were more likely to be Aβ positive ( p < 0.006). APOE ‐ε4 homozygotes were less likely to initiate lecanemab (HR = 0.11, p < 0.001). DISCUSSION The adoption of anti‐Aβ therapies coincided with a rapid shift in diagnostic workflows.
Practical Interpretation of Bone Scintigraphy: Metastases, Fractures, and Beyond
Haug, Logan P. , Brown, Parker J. , Bishay, Steven , Lombardi, Alecio F. , Huang, Steve S. , Shin, Clifford , Koran, Mary Ellen I. , Long, J. B., Martínez, Felipe Derteano, Nguyen, Ba D. , Long, Jeremiah R. , Bishay, Steven E , Long, Jeremiah , Martinez, Felipe , Nguyen, B D , Koran, Mary Ellen
RadioGraphics | January 15, 2026 | Volume: 46 | Issue: 2 | Pages: No page available
Bone scintigraphy is a valuable adjunct to cross-sectional imaging and can be used to evaluate disease extent in multifocal processes such as blastic osseous metastatic disease, provide diagnostic information to aid in problem solving in challenging cases, and serve as the primary diagnostic modality for diseases that manifest with pathognomonic scintigraphic appearances.